MGMT and central nervous system cancer: Barbara et al. [89] employed CRISPR/Cas9 technology to induce MGMT reordering in glioma cells, discovering that genomic rearrangement permits regulation by more active promoters, leading to increased MGMT expression and enhancement of TMZ resistance.